Endologix, Inc. (ELGX) Trading Up 5.6%
Endologix, Inc. (NASDAQ:ELGX)’s share price was up 5.6% during mid-day trading on Tuesday . The stock traded as high as $6.28 and last traded at $6.25. Approximately 1,300,349 shares were traded during mid-day trading, an increase of 150% from the average daily volume of 520,041 shares. The stock had previously closed at $5.92.
Several equities analysts recently issued reports on ELGX shares. Canaccord Genuity restated a “hold” rating on shares of Endologix in a report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 price objective on shares of Endologix and gave the company a “hold” rating in a report on Thursday, August 3rd. Stifel Nicolaus set a $6.00 price objective on shares of Endologix and gave the company a “hold” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada reiterated a “hold” rating and set a $5.00 price objective on shares of Endologix in a report on Monday, July 31st. Finally, Zacks Investment Research lowered shares of Endologix from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 25th. Two analysts have rated the stock with a sell rating and eleven have given a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $6.28.
The company has a debt-to-equity ratio of 2.28, a quick ratio of 2.12 and a current ratio of 2.82.
Several institutional investors have recently added to or reduced their stakes in ELGX. Redmile Group LLC grew its position in shares of Endologix by 134.4% during the 2nd quarter. Redmile Group LLC now owns 6,368,299 shares of the medical instruments supplier’s stock valued at $30,950,000 after acquiring an additional 3,650,905 shares during the period. Vanguard Group Inc. lifted its stake in Endologix by 5.6% in the 2nd quarter. Vanguard Group Inc. now owns 6,638,302 shares of the medical instruments supplier’s stock worth $32,262,000 after purchasing an additional 353,233 shares in the last quarter. State Street Corp lifted its position in Endologix by 11.5% during the 2nd quarter. State Street Corp now owns 1,951,432 shares of the medical instruments supplier’s stock valued at $9,483,000 after acquiring an additional 201,700 shares during the period. Renaissance Technologies LLC grew its position in Endologix by 46.3% during the first quarter. Renaissance Technologies LLC now owns 503,891 shares of the medical instruments supplier’s stock valued at $3,648,000 after buying an additional 159,369 shares during the period. Finally, Marshall Wace North America L.P. boosted its position in shares of Endologix by 277.3% in the second quarter. Marshall Wace North America L.P. now owns 173,939 shares of the medical instruments supplier’s stock worth $870,000 after purchasing an additional 127,838 shares during the period.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.